China will implement new cybersecurity rules that include stricter consent requirements and also expand cross-border data exemptions; A Beijing court rules that consent is not required for presenting lawfully collected personal information in court; and China is increasingly exporting its technology, engineering, supply chain, and financing capacity.
Legitimate presenting of personal information in court does not require an individual's consent.
Bayer successfully files for the first cross-border data transfer in Beijing Free Trade Zone; Yuanbao plans to list on Nasdaq after some Chinese IPO successes, but setbacks also exist; and China's environmental regulator merges approval procedures to encourage private business
Network virtualization needs to provide data encryption protection and satisfy security requirements.
Casper Sek and Alan Zhang of Jingtian & Gongcheng analyze the first court judgment on cross-border data transfer, which answers practical questions relating to the operation of the Personal Information Protection Law in the context of a hotel booking app, and prompts companies to review their privacy policies
Chinese company sues Texas power operator for blocking investment approved by CFIUS; China delays retirement age to relieve pressure on pensions; and China proposes identification and labeling requirements for AI-generated content
China allows fully foreign-owned hospitals and foreign investment in gene technologies; China is assessing the compatibility of the international AI agreement with its own strategic plans; and China's Ministry of Finance strengthens its regulation of foreign accounting organizations, particularly for those that do not have offices in China
Chinese court rules against international hotel brand for misuse of cross-border personal data; EU and China establish mechanism to address difficulties in data transfers; and High-frequency futures traders question their survival in an increasingly hostile Chinese futures market
U.S. lawmakers call on the government to scrutinize drugmakers' clinical trials in China; China removes restrictions for foreign investments in the manufacturing and services industries; and Cross-Boundary Wealth Connect gains 10 new additional securities firms for increased offshore investment opportunities.
Export pharmaceuticals commissioned for production from a foreign pharmaceutical manufacturer may not be sold and used in the PRC
